Literature DB >> 35344931

Application of Urine and Copro Antigen Assays after Primary Infection and Drug Treatment in an Experimental Opisthorchiasis Animal Model.

Chanika Worasith1,2, Kulthida Y Kopolrat2, Opal Pitaksakulrat1, Chutima Homwong2, Yingpinyapat Kittirat2,3, Phattharaphon Wongphutorn2,4, Jiraporn Sithithaworn5, Paiboon Sithithaworn1,2.   

Abstract

Infection by Opisthorchis viverrini causes significant health problems, including cholangiocarcinoma (CCA); thus control and elimination of this trematode is an important strategy for the reduction of CCA. Currently, urine and copro antigen detection is more sensitive than parasitological examination of the feces for the diagnosis of opisthorchiasis. Given limitations in human studies, we used an animal model to quantify the parasite antigen profiles in urine and feces in O. viverrine-infected hamsters, and postdrug treatment. The positive detections of O. viverrini antigen began from week 1 in urine and week 2 in feces after infection until week 28 of the study. The recoveries of O. viverrini worms were detected starting from week 1 and eggs of O. viverrini were detected in feces from week 3 after infection and remained detectable throughout the study period. There was a significant positive correlation of urine and copro antigen levels with the number of fecal egg counts (P < 0.01) and worm recovery (P < 0.01). In the drug-treatment experiment, treatment of infected hamsters with praziquantel significantly reduced worm burden, fecal egg output, and antigen in urine and feces compared with the untreated controls (P < 0.001). At 4 weeks posttreatment, the egg and worm reduction rates were 100% and 95.5%, respectively. The positive antigen detections in urine and feces corresponded with partial worm clearance from praziquantel treatment. This study demonstrated a direct link of urine and copro antigen tests with worms infecting the liver thereby reaffirming the reliability of urine and copro antigen assay in opisthorchiasis diagnosis.

Entities:  

Year:  2022        PMID: 35344931      PMCID: PMC9128695          DOI: 10.4269/ajtmh.21-1145

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   3.707


  33 in total

1.  Development of immune-complex glomerulonephritis and amyloidosis in Syrian golden hamsters infected with Opisthorchis viverrini.

Authors:  S Boonpucknavig; V Boonpucknavig; S Tanvanich; G Doungchawee; W Thamavit
Journal:  J Med Assoc Thai       Date:  1992-01

2.  Detection of Opisthorchis viverrini antigens in stools using specific monoclonal antibody.

Authors:  W Chaicumpa; L Ybanez; V Kitikoon; S Pungpak; Y Ruangkunaporn; M Chongsa-nguan; S Sornmani
Journal:  Int J Parasitol       Date:  1992-07       Impact factor: 3.981

3.  Improved performance and quantitative detection of copro-antigens by a monoclonal antibody based ELISA to diagnose human opisthorchiasis.

Authors:  Nattaya Watwiengkam; Jiraporn Sithithaworn; Kunyarat Duenngai; Banchob Sripa; Thewarach Laha; Maria Vang Johansen; Paiboon Sithithaworn
Journal:  Acta Trop       Date:  2013-09-18       Impact factor: 3.112

4.  Opisthorchis viverrini antigen induces the expression of Toll-like receptor 2 in macrophage RAW cell line.

Authors:  Somchai Pinlaor; Saeko Tada-Oikawa; Yusuke Hiraku; Porntip Pinlaor; Ning Ma; Paiboon Sithithaworn; Shosuke Kawanishi
Journal:  Int J Parasitol       Date:  2005-03-11       Impact factor: 3.981

Review 5.  The current status of opisthorchiasis and clonorchiasis in the Mekong Basin.

Authors:  Paiboon Sithithaworn; Ross H Andrews; Van De Nguyen; Thitima Wongsaroj; Muth Sinuon; Peter Odermatt; Yukifumi Nawa; Song Liang; Paul J Brindley; Banchob Sripa
Journal:  Parasitol Int       Date:  2011-08-25       Impact factor: 2.230

6.  Application of urine antigen assay to evaluate outcomes of praziquantel treatment and reinfection in opisthorchiasis in northeast Thailand.

Authors:  Chanika Worasith; Chompunoot Wangboon; Kulthida Y Kopolrat; Chutima Homwong; Jiraporn Sithithaworn; Anchalee Techasen; Raynoo Thanan; Narong Khuntikeo; Paiboon Sithithaworn
Journal:  Trans R Soc Trop Med Hyg       Date:  2020-10-05       Impact factor: 2.184

7.  Studies on the chemotherapy of human opisthorchiasis: III. Minimum effective dose of praziquantel.

Authors:  D Bunnag; T Harinasuta
Journal:  Southeast Asian J Trop Med Public Health       Date:  1981-09       Impact factor: 0.267

8.  Urine-based antigen detection assay for diagnosis of visceral leishmaniasis using monoclonal antibodies specific for six protein biomarkers of Leishmania infantum / Leishmania donovani.

Authors:  Claudia Abeijon; Fabiana Alves; Séverine Monnerat; Jane Mbui; Agostinho G Viana; Raquel M Almeida; Lilian L Bueno; Ricardo T Fujiwara; Antonio Campos-Neto
Journal:  PLoS Negl Trop Dis       Date:  2020-04-23

9.  Comparing the performance of urine and copro-antigen detection in evaluating Opisthorchis viverrini infection in communities with different transmission levels in Northeast Thailand.

Authors:  Chanika Worasith; Chompunoot Wangboon; Kunyarat Duenngai; Nadda Kiatsopit; Kulthida Kopolrat; Anchalee Techasen; Jiraporn Sithithaworn; Narong Khuntikeo; Watcharin Loilome; Nisana Namwat; Puangrat Yongvanit; Elizabeth J Carlton; Paiboon Sithithaworn
Journal:  PLoS Negl Trop Dis       Date:  2019-02-08

Review 10.  Current Perspectives on Opisthorchiasis Control and Cholangiocarcinoma Detection in Southeast Asia.

Authors:  Narong Khuntikeo; Attapol Titapun; Watcharin Loilome; Puangrat Yongvanit; Bandit Thinkhamrop; Nittaya Chamadol; Thidarat Boonmars; Teerachai Nethanomsak; Ross H Andrews; Trevor N Petney; Paiboon Sithithaworn
Journal:  Front Med (Lausanne)       Date:  2018-04-30
View more
  1 in total

1.  Effects of day-to-day variation of Opisthorchis viverrini antigen in urine on the accuracy of diagnosing opisthorchiasis in Northeast Thailand.

Authors:  Chanika Worasith; Phattharaphon Wongphutorn; Chutima Homwong; Kulthida Y Kopolrat; Anchalee Techasen; Raynoo Thanan; Chatanun Eamudomkarn; Chompunoot Wangboon; Narong Khuntikeo; Watcharin Loilome; Jiraporn Sithithaworn; Thomas Crellen; Paiboon Sithithaworn
Journal:  PLoS One       Date:  2022-07-19       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.